Browse our 650+ Publications
Latest Publications
Neoadjuvant Immunotherapy Leads to Pathological Responses in MMR-proficient and MMR-deficient Early-Stage Colon Cancers
Chalabi et al.
Nature Medicine
April 2020
Authors and Affiliates
Myriam Chalabi 1 2 3, Lorenzo F Fanchi 4 5, Krijn K Dijkstra 4 5, José G Van den Berg 6, Arend G Aalbers 7, Karolina Sikorska 8, Marta Lopez-Yurda 8 9, Cecile Grootscholten 10, Geerard L Beets 7 11, Petur Snaebjornsson 6, Monique Maas 12, Marjolijn Mertz 13, Vivien Veninga 4 5, Gergana Bounova 5 14, Annegien Broeks 15, Regina G Beets-Tan 11 12, Thomas R de Wijkerslooth 10, Anja U van Lent 16, Hendrik A Marsman 17, Elvira Nuijten 8, Niels F Kok 7, Maria Kuiper 10, Wieke H Verbeek 10, Marleen Kok 18 19, Monique E Van Leerdam 10, Ton N Schumacher 4 5, Emile E Voest 20 21 22, John B Haanen 4 18;
1Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. m.chalabi@nki.nl.
2Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. m.chalabi@nki.nl.
3Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. m.chalabi@nki.nl.
4Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
5Oncode Institute, Utrecht, the Netherlands.
6Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
7Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
8Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
9Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
10Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
11GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.
12Radiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
13Bioimaging Facility, Netherlands Cancer Institute, Amsterdam, the Netherlands.
14Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands.
15Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands.
16Gastroenterology & Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.
17Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.
18Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
19Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
20Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. e.voest@nki.nl.
21Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. e.voest@nki.nl.
22Oncode Institute, Utrecht, the Netherlands. e.voest@nki.nl.
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
Phillips et al.
JAMA Oncology
March 2020
Authors and Affiliates
Ryan Phillips, MD, PhD1; William Yue Shi, BS2; Matthew Deek, MD1; Noura Radwan, MD1; Su Jin Lim, ScM3; Emmanuel S. Antonarakis, MD3; Steven P. Rowe, MD, PhD4,5; Ashley E. Ross, MD, PhD5; Michael A. Gorin, MD4,5; Curtiland Deville, MD1; Stephen C. Greco, MD1; Hailun Wang, PhD1; Samuel R. Denmeade, MD3; Channing J. Paller, MD3; Shirl Dipasquale, MS, RN1; Theodore L. DeWeese, MD1,3,5; Daniel Y. Song, MD1,3,5; Hao Wang, PhD3; Michael A. Carducci, MD3; Kenneth J. Pienta, MD3,5; Martin G. Pomper, MD, PhD4,5; Adam P. Dicker, MD, PhD6; Mario A. Eisenberger, MD3; Ash A. Alizadeh, MD, PhD7; Maximilian Diehn, MD, PhD2; Phuoc T. Tran, MD, PhD1,3,5
Author Affiliations Article Information
1Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
2Stanford Cancer Institute, Department of Radiation Oncology, School of Medicine, Stanford University, Stanford, California
3Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
4The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
5The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland
6Sidney Kimmel Cancer Center, Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania
7Stanford Cancer Institute, Division of Oncology, Department of Medicine, School of Medicine, Stanford University, Stanford, California
Epstein-Barr Virus Epitope-Major Histocompatibility Complex Interaction Combined with Convergent Recombination Drives Selection of Diverse T Cell Receptor α and β Repertoires
Gil et al.
mBio
March 2020
Authors and Affiliates
Gil A#1, Kamga L#2, Chirravuri-Venkata R3, Aslan N1, Clark F1, Ghersi D3, Luzuriaga K#4, Selin LK#5;
1
Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
2
Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
3
School of Interdisciplinary Informatics, University of Nebraska at Omaha, Omaha, Nebraska, USA.
4
Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA katherine.luzuriaga@umassmed.edu liisa.selin@umassmed.edu.
5
Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, USA katherine.luzuriaga@umassmed.edu liisa.selin@umassmed.edu.
#
Contributed equally
Prevalent and diverse intratumoral oncoprotein-specific CD8+ T cells within polyoma virus-driven Merkel cell carcinomas
Jing et al.
Cancer Immunology Research
March 2020
Authors and Affiliates
Lichen Jing 1, Mariliis Ott 1, Candice D. Church 2, Rima M. Kulikauskas 2, Dafina Ibrani 2, Jayasri G. Iyer 2, Olga K. Afanasiev 2, Aric Colunga 2, Maclean M. Cook 2, Hong Xie 6, Alexander L. Greninger 6, Kelly G. Paulson 8,3, Aude G. Chapuis 8,3, Shailender Bhatia 8,3, Paul Nghiem 2,3, David M. Koelle 1,4,5,6,7,9
1 Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA
2 Division of Dermatology, Department of Medicine, University of Washington, Seattle, WA, USA 3 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
4 Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
5 Department of Global Health, University of Washington, Seattle, WA, USA
6 Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
7 Benaroya Research Institute, Seattle, WA, USA
8 Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
9 Correspondence at: 750 Republican Street, Room E651, Seattle, WA, 98109, USA; tel 206 616 1940; fax 206 616 4898, email dkoelle@medicine.washington.edu
Peripheral T cell expansion predicts tumour infiltration and clinical response
Wu et al.
Nature
February 2020
Authors and Affiliates
Wu TD1, Madireddi S2, de Almeida PE2, Banchereau R3, Chen YJ4, Chitre AS2, Chiang EY2, Iftikhar H2, O'Gorman WE5, Au-Yeung A5, Takahashi C5, Goldstein LD6, Poon C7, Keerthivasan S2, de Almeida Nagata DE2, Du X2, Lee HM2, Banta KL2, Mariathasan S3, Das Thakur M8, Huseni MA8, Ballinger M8, Estay I8, Caplazi P9, Modrusan Z4, Delamarre L2, Mellman I2, Bourgon R6, Grogan JL10;
1
Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, CA, USA. twu@gene.com.
2
Department of Cancer Immunology, Genentech, Inc., South San Francisco, CA, USA.
3
Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.
4
Department of Microchemistry, Proteomics, Lipidomics and Next Generation Sequencing, Genentech, Inc., South San Francisco, CA, USA.
5
Department of OMNI Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.
6
Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, CA, USA.
7
Department of Research Biology, Genentech, Inc., South San Francisco, CA, USA.
8
Department of Development Sciences, Genentech, Inc., South San Francisco, CA, USA.
9
Department of Pathology, Genentech, Inc., South San Francisco, CA, USA.
10
ArsenalBio, South San Francisco, CA, USA. jane@arsenalbio.com.
Immuno-genomic landscape of osteosarcoma
Wu et al.
Nature Communications
February 2020
Authors and Affiliates
Wu CC1, Beird HC1, Andrew Livingston J2,3, Advani S3, Mitra A1, Cao S4, Reuben A5, Ingram D6, Wang WL6, Ju Z4, Hong Leung C7, Lin H7, Zheng Y1, Roszik J1, Wang W4, Patel S2, Benjamin RS2, Somaiah N2, Conley AP2, Mills GB8, Hwu P2, Gorlick R3, Lazar A6, Daw NC3, Lewis V9, Futreal PA10;
1
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
2
Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
3
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
4
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
5
Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
6
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
7
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
8
Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
9
Department of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
10
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. afutreal@mdanderson.org.
Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
Aslan et al.
Nature Communications
February 2020
Authors and Affiliates
Aslan K1,2,3,4, Turco V1,2, Blobner J1,2, Sonner JK1,2,5, Liuzzi AR6, Núñez NG6, De Feo D6, Kickingereder P7, Fischer M7, Green E1,2, Sadik A8, Friedrich M1,2, Sanghvi K1,2,3, Kilian M1,2,3, Cichon F1,2,3, Wolf L1,2, Jähne K1,2, von Landenberg A1,2, Bunse L1,2, Sahm F9,10, Schrimpf D9,10, Meyer J9,10, Alexander A1,3,7, Brugnara G7, Röth R11, Pfleiderer K1,7, Niesler B11, von Deimling A9,10, Opitz C8, Breckwoldt MO1,7, Heiland S7, Bendszus M7, Wick W12,13,14, Becher B6, Platten M15,16,17;
1
DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
2
Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany.
3
Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
4
Immatics Biotechnologies GmbH, Tübingen, Germany.
5
Institute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
6
Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
7
Department of Neuroradiology, Heidelberg University Medical Center, Heidelberg, Germany.
8
Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
9
DKTK Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
10
Department of Neuropathology, Heidelberg University Medical Center, Heidelberg, Germany.
11
nCounter Core Facility, Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
12
Department of Neurology, Heidelberg University Medical Center, Heidelberg, Germany.
13
National Center for Tumor Diseases Heidelberg, DKTK, Heidelberg, Germany.
14
DKTK CCU Neurooncology, DKFZ, Heidelberg, Germany.
15
DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.platten@dkfz-heidelberg.de.
16
Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany. m.platten@dkfz-heidelberg.de.
17
Helmholtz Institute for Tranlational Oncology (HI-TRON), Mainz, Germany. m.platten@dkfz-heidelberg.de.
T Cell Repertoire in Combination with T cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma
Farah et al.
Journal of Investigative Dermatology
February 2020
Authors and Affiliates
Maya Farah1,*, Alexandre Reuben2,*, Ivelina Spassova3, Richard K. Yang1, Linda Kubat3, Priyadharsini Nagarajan1, Jing Ning4, Wen Li4, Phyu P. Aung1, Jonathan L. Curry1,5,6, Carlos A. Torres-Cabala1,5, Courtney W. Hudgens6, Selma Ugurel7, Dirk Schadendorf7, Curtis Gumbs8, Latasha D. Little8, Andrew Futreal8, Ignacio I. Wistuba6, Victor G. Prieto1,5, Linghua Wang8, Michael K. Wong9, Jennifer A. Wargo8,10, Jürgen C. Becker3,7,11,, and Michael T. Tetzlaff1,6,; The University of Texas MD Anderson Cancer Center
1 Department of Pathology and Laboratory Medicine
2 Department of Thoracic/Head & Neck Medical Oncology 3Translational Skin Cancer Research, University Clinic Essen, Germany 4 Department of Biostatistics
5 Department of Dermatology
6 Department of Translational and Molecular Pathology
7 Department of Dermatology, University Clinic Essen, Germany
8 Department of Genomic Medicine
9 Department of Melanoma Medical Oncology
10Department of Surgical Oncology
11German Cancer Consortium (DKTK), German Cancer Center (DKFZ), Heidelberg, Germany
Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R- Dependent STING Activation by Tumor-Derived cGAMP
Zhou et al.
Immunity
February 2020
Authors and Affiliates
Yi Zhou,1,3 Mingjian Fei,1,3 Gu Zhang,1 Wei-Ching Liang,1 WeiYu Lin,1 Yan Wu,1 Robert Piskol,1 John Ridgway,1
Erin McNamara,1 Haochu Huang,1 Juan Zhang,1 Jaehak Oh,1 Jaina M. Patel,2 Diana Jakubiak,1 Jeff Lau,1
Beth Blackwood,1 Daniel D. Bravo,1 Yongchang Shi,1 Jianyong Wang,1 Hong-Ming Hu,2 Wyne P. Lee,1 Rajiv Jesudason,1 Dewakar Sangaraju,1 Zora Modrusan,1 Keith R. Anderson,1 Søren Warming,1 Merone Roose-Girma,1
and Minhong Yan1,4,*
1Genentech Inc., South San Francisco, CA, USA
2Cancer Immunobiology Laboratory, Earle A. Chiles Research Institute, Portland, OR, USA
3These authors contributed equally
4Lead Contact
*Correspondence: minhong@gene.com